P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials

Liknande verk

• P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials
  av: Andrea Doria, et al.
  Utgiven: (2024-03-01)
• O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials
  av: Andrea Doria, et al.
  Utgiven: (2024-03-01)
• SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies
  av: Andrea Doria, et al.
  Utgiven: (2025-05-01)
• Complement and autoantibody levels under anifrolumab therapy in SLE: implications for clinical practice
  av: Jan-Gerd Rademacher, et al.
  Utgiven: (2026-03-01)
• Worse cardiovascular and renal outcome in male SLE patients
  av: Jelena Mihailovic, et al.
  Utgiven: (2023-10-01)